CRSPCRISPR Therapeutics AG
Price
-14%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growth fading, the market undecided.
Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Its largest product in Jun 2026 was Collaboration at $10M, 98% of the disclosed total, well ahead of Grant at 1.8%. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jun 4, 2026Approval of CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan On June 4, 2026, at the 2026 Annual General Meeting of Shareholders (the “Annual Meeting”), the shareholders of CRISPR Therapeutics AG (the “Company”) approved the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan (the “2026 Plan”)Director or officer change · Form 8-K
- May 4, 2026CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $10.2MThe company’s own SEC segment disclosure.
- Collaboration$10.0M98%
- Grant$181.0K2%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry